Walgreen (NYSE: WAG ) reported a slight miss on bottom line earnings this week, prompting general unhappiness about the company's sluggish growth as it (and competitor Rite Aid, which also recently reported) deals with drug reimbursement pressure that is eroding margins.
But there are some silver linings for Walgreen investors -- synergies with Alliance Boots appear likely to come in ahead of previous estimates (judging by management raising expectations to nearly half a billion dollars for this fiscal year), and same-store sales increased smoothly, despite some decline in store traffic.
But Walgreen's most important silver lining is definitely the potential Alliance Boots acquisition -- and in the video below, health care analysts Michael Douglass and David Williamson lay out why investors should watch Walgreen's upcoming decision on the acquisition.
Leaked: This coming opportunity could leave Walgreen in the dust
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.